SEC Form 4 · Rule 10b5-1 trading plans
Krystal Biotech, Inc. (KRYS)
- 51Trades filed under a plan
- 2Plan adoption dates stated
- 6Quarterly results prints on file
- 0Trades in the days before a print
In the 2025 filing year, Krystal Biotech, Inc. filed 7 Form 4 statements whose footnotes name a Rule 10b5-1 trading plan, by 3 reporting owners, covering 51 transactions filed under those plans and 200,750 shares. None carries the SEC's own AFF10B5ONE adoption flag; each of the 7 names a plan in a footnote. 6 results prints are on file in the same window, which is what makes the interval below measurable.
Trades filed under a plan in Krystal Biotech, Inc. 51
- ROMANO KATHRYN — 2025-02-27 · S · 750 shares
- Krishnan Krish S — 2025-03-13 · S · 1,100 shares
- Krishnan Krish S — 2025-03-13 · S · 4,944 shares
- Krishnan Krish S — 2025-03-13 · S · 10,931 shares
- Krishnan Krish S — 2025-03-13 · S · 6,769 shares
- Krishnan Krish S — 2025-03-13 · S · 1,256 shares
- Krishnan Krish S — 2025-03-13 · S · 1,639 shares
- Krishnan Krish S — 2025-03-13 · S · 4,579 shares
- Krishnan Krish S — 2025-03-13 · S · 10,937 shares
- Krishnan Krish S — 2025-03-13 · S · 6,514 shares
- Krishnan Krish S — 2025-03-13 · S · 1,331 shares
- Krishnan Suma — 2025-03-13 · S · 1,639 shares
Plan adoption dates stated in Krystal Biotech, Inc. 2
- 2024-06-13 — stated in 2 filings
- 2024-09-12 — stated in 2 filings
Quarterly results prints on file in Krystal Biotech, Inc. 6
- 2025-05-06
- 2025-08-04
- 2025-11-03
- 2026-01-12
- 2026-02-17
- 2026-08-03
Trades in the days before a print in Krystal Biotech, Inc. 0
- 19 days before the 2025-08-04 print — 2025-07-16 · S · Krishnan Krish S · 1,389 shares
- 19 days before the 2025-08-04 print — 2025-07-16 · S · Krishnan Krish S · 1,529 shares
- 19 days before the 2025-08-04 print — 2025-07-16 · S · Krishnan Suma · 1,529 shares
- 19 days before the 2025-08-04 print — 2025-07-16 · S · Krishnan Suma · 1,389 shares
- 20 days before the 2025-08-04 print — 2025-07-15 · S · Krishnan Krish S · 2,184 shares
- 20 days before the 2025-08-04 print — 2025-07-15 · S · Krishnan Krish S · 900 shares
- 20 days before the 2025-08-04 print — 2025-07-15 · S · Krishnan Krish S · 2,236 shares
- 20 days before the 2025-08-04 print — 2025-07-15 · S · Krishnan Krish S · 800 shares
- 20 days before the 2025-08-04 print — 2025-07-15 · S · Krishnan Suma · 2,236 shares
- 20 days before the 2025-08-04 print — 2025-07-15 · S · Krishnan Suma · 800 shares
- 20 days before the 2025-08-04 print — 2025-07-15 · S · Krishnan Suma · 2,184 shares
- 20 days before the 2025-08-04 print — 2025-07-15 · S · Krishnan Suma · 900 shares
Interval to the next reported results date
For each transaction filed under a plan, the days between the transaction date and the company’s next results print. These are the dates the filings state, printed as an interval; the page draws no conclusion from them.
- 0Within 5 days of a print
- 0Within 10 days of a print
- 19Shortest interval, in days
- 0Trades with no later print on file
Adoption dates, as the filings state them
- 2024-06-13 stated in 2 filings
- 2024-09-12 stated in 2 filings
As the filings state it: “10b5-1 trading plan adopted by the Reporting Person on June 13, 2024”
Reported results dates on file
- 2025-05-06
- 2025-08-04
- 2025-11-03
- 2026-01-12
- 2026-02-17
- 2026-08-03
A proxy statement is on file for this company in the same window, which is where a company states its own trading policy.
Other companies with plan records
- BRISTOL MYERS SQUIBB CO 1
- FMC CORP 2
- ELI LILLY & Co 4
- ABEONA THERAPEUTICS INC. 2
- HEXCEL CORP /DE/ 2
- TEVA PHARMACEUTICAL INDUSTRIES LTD 12
- Lifevantage Corp 1
- IONIS PHARMACEUTICALS INC 29
- VERTEX PHARMACEUTICALS INC / MA 22
- ARROWHEAD PHARMACEUTICALS, INC. 9
Order the document
Every company with plan records →
Form 4 statements and their footnotes from the SEC’s EDGAR full-text search, and this company’s results dates, industry classification and state of incorporation from the SEC submissions API. The page prints the dates the filings state and the interval between them; it draws no conclusion from them.